Committed to Bettering Lives Through Cannabis
For the patient finding relief, the person rediscovering balance, the consumer who expects better. We're building the cannabis company you deserve — principled, disciplined, and relentlessly focused on you.
OUR BRANDS
From premium flower to purpose-built medical products, our brand portfolio is designed for quality, consistency, and experiences worth having.
Explore Our Brands
Investor Relations
A disciplined operator, a growing global footprint, and a clear ambition to lead the world's next great consumer category.
Lean More
About us
Who We Are
Cannabis is a global economic force in the making. The companies that lead won't be those who move fastest, but those who are principled, disciplined, and relentlessly focused on the consumer.
We are building that company. Consumer-obsessed, focused, and built for the long term – bettering lives for our people, our communities, our consumers, and our shareholders.
News & Press
Latest News and Press
July 24, 2026
Canopy Growth to Report First Quarter Fiscal 2027 Financial Results on August 7, 2026
SMITHS FALLS, ON – July 24, 2026 – Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) will release its financial results for the first quarter fiscal year 2027 ended June 30, 2026 before financial markets open on August 7, 2026.
July 21, 2026
Canopy Growth Announces Participation at Upcoming Canaccord Genuity Growth Conference
SMITHS FALLS, ON – July 21, 2026 – Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC) announced it will be participating at the Canaccord Genuity Growth Conference in August 2026.
June 15, 2026
Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis
Full-year 2026 growth driven by net revenue increases of 20% in Canada adult-use cannabis and 18% in Canada medical Completed acquisition of MTL Cannabis, positioning Canopy Growth as Canada’s leading medical cannabis company by revenue Ended the fiscal year with $131.3M of net cash following strategic recapitalization completed in January 2026 Strategic decisions and financial